“Our first priority of course is to develop and produce enough quantity of safe and effective FDA-approved vaccines and therapeutics for use in the United States,” Azar said, according to Reuters.

“But we anticipate having capacity that, once those needs are satisfied, those products would be available in the world community according to fair and equitable distributions that we would consult in the international community on,” he said, according to Reuters…

“After our departure from the WHO, we will work with others in the world community to find the appropriate vehicles for continuing to support, on a multilateral and bilateral basis, global public health on the order that the United States has done in the past,” Azar said.